On May 19, 2021 Targovax ASA’s ("Targovax" or the "Company") stock exchange reported that Published on 18 May 2021, regarding the board of directors’ resolution to increase the Company’s share capital with NOK 2,129.90 by the issuance of 21,299 new shares, each with a nominal value of NOK 0.10, in order to facilitate an exercise of 21,299 RSUs pursuant to the Company’s RSU program for Board members (Press release, Targovax, MAY 19, 2021, View Source [SID1234580281]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Primary insider, Bente-Lill Romøren, member of the board of directors, has exercised

15,250 restrictive stock units ("RSUs") under her RSU agreement and subscribed for 15,250 new shares in the Company following the exercise of RSUs. The exercise price for the options was NOK 0.10 per new share.

Following the RSU exercise and subscription of new shares and the registration of the share capital increase pertaining to the new shares with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), Bente-Lilll Romøren holds 35,577 shares, 11,361 RSUs and nil options in Targovax.